Export translations

Settings

Group

Language

Format

Export for off-line translation

Export in native format

Export in CSV format

<languages />
<div lang="en" dir="ltr" class="mw-content-ltr">
{{short description|Accumulation of degenerative material in the inner layer of artery walls}}
{{Infobox medical condition (new)
| name            = Atheroma
| synonyms        = atheromata (''plural''), atheromas (''plural''), atheromatous plaque, plaque
| image           = Carotid Plaque.jpg
| caption         = Atherosclerotic plaque from a [[carotid endarterectomy]] specimen. This shows the division of the [[common carotid artery|common]] into the [[internal carotid artery|internal]] and [[external carotid artery|external carotid arteries]].
| pronounce       =
| field           =
| symptoms        =
| complications   = [[Thrombosis]], [[embolism]], [[atherosclerosis]], [[arteriosclerosis]]
| onset           =
| duration        =
| types           =
| causes          = [[Hyperlipidemia]], [[hypertriglyceridemia]], [[hypercholesterolemia]]
| risks           =
| diagnosis       =
| differential    =
| prevention      =
| treatment       =
| medication      =
| prognosis       =
| frequency       =
| deaths          =
}}
An '''atheroma''', or '''atheromatous plaque''', is an abnormal accumulation of material in the [[tunica intima|inner layer]] of an [[arterial]] wall.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
The material consists of mostly [[macrophage|macrophage cells]], or debris, containing [[lipids]], calcium and a variable amount of fibrous [[connective tissue]]. The accumulated material forms a swelling in the artery wall, which may intrude into the [[Lumen (anatomy)|lumen]] of the artery, [[stenosis|narrowing]] it and restricting blood flow. Atheroma is the [[pathological]] basis for the disease entity [[atherosclerosis]], a subtype of [[arteriosclerosis]].
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
==Signs and symptoms==
For most people, the first symptoms result from atheroma progression within the [[coronary arteries|heart arteries]], most commonly resulting in a [[myocardial infarction|heart attack]] and ensuing debility. The heart arteries are difficult to track because they are small (from about 5&nbsp;mm down to microscopic), they are hidden deep within the chest and they never stop moving.  Additionally, all mass-applied clinical strategies focus on both minimal cost and  the overall safety of the procedure. Therefore, existing diagnostic strategies for detecting atheroma and tracking response to treatment have been extremely limited. The methods most commonly relied upon, patient symptoms and [[cardiac stress testing]], do not detect any symptoms of the problem until atheromatous disease is very advanced because arteries enlarge, not constrict, in response to increasing atheroma. It is plaque ruptures, producing debris and clots which obstruct blood flow downstream, sometimes also locally (as seen on [[angiogram]]s), which reduce/stop blood flow. Yet these events occur suddenly and are not revealed in advance by either [[Cardiac stress test|stress tests]]
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
==Mechanism==
The healthy epicardial coronary artery consists of three layers, the [[tunica intima]], media, and [[adventitia]]. Atheroma and changes in the artery wall usually result in small [[aneurysm]]s (enlargements) just large enough to compensate for the extra wall thickness with no change in the lumen diameter. However, eventually, typically as a result of rupture of [[vulnerable plaque]]s and clots within the lumen over the plaque, [[stenosis]] (narrowing) of the vessel develops in some areas. Less frequently, the artery enlarges so much that a gross aneurysmal enlargement of the artery results. All three results are often observed, at different locations, within the same individual.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
===Stenosis and closure===
Over time, atheromata usually progress in size and thickness and induce the surrounding muscular central region (the media) of the [[artery]] to stretch out, which is termed ''remodeling''. Typically, remodeling occurs just enough to compensate for the atheroma's size such that the [[Caliber|calibre]] of the artery opening ([[Lumen (anatomy)|lumen]]) remains unchanged, until about 50% of the artery wall cross-sectional area consists of atheromatous tissue.
[[File:Atheroma.jpg|thumb|302x302px|Narrowed arterial blood vessel blocked with an atheroma (artist's conception).]]
If the muscular wall enlargement eventually fails to keep up with the enlargement of the atheroma volume, or a clot forms and organizes over the plaque, then the lumen of the artery becomes narrowed as a result of repeated ruptures, clots and fibrosis over the tissues separating the atheroma from the blood stream. This narrowing becomes more common after decades of living, increasingly more common after people are in their 30s to 40s.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
The [[endothelium]] (the cell monolayer on the inside of the vessel) and covering tissue, termed [[fibrous cap]], separate atheroma from the blood in the lumen. If a rupture (see [[vulnerable plaque]]) of the endothelium and fibrous cap occurs, then both a shower of debris from the plaque (debris larger than 5 micrometres are too large to pass through [[capillary|capillaries]]) combined with a [[platelet]] and [[clotting]] response (an injury/repair response to both the debris and at the rupture site) begins within fractions of a second, eventually resulting in narrowing or sometimes closure of the lumen. Eventually downstream tissue damage occurs due to closure or obstruction of downstream microvessels and/or closure of the lumen at the rupture, both resulting in loss of blood flow to downstream tissues. This is the principal mechanism of [[myocardial infarction]], [[stroke]] or other related [[cardiovascular disease]] problems.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
While clots at the rupture site typically shrink in volume over time, some of the clot may become organized into fibrotic tissue resulting in narrowing of the artery lumen; the narrowings sometimes seen on [[angiography]] examinations, if severe enough. Since angiography methods can only reveal larger lumens, typically larger than 200 micrometres, angiography after a cardiovascular event commonly does not reveal what happened.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
===Artery enlargement===
If the muscular wall enlargement is overdone over time, then a gross [[aneurysm|enlargement]] of the artery results, usually over decades of living. This is a less common outcome. Atheroma within aneurysmal enlargement (vessel bulging) can also rupture and shower debris of atheroma and clot downstream. If the arterial enlargement continues to 2 to 3 times the usual diameter, the walls often become weak enough that with just the stress of the pulse, a loss of wall integrity may occur leading to sudden [[hemorrhage]] (bleeding), major symptoms and debility; often rapid death. The main stimulus for aneurysm formation is pressure atrophy of the structural support of the muscle layers. The main structural proteins are [[collagen]] and [[elastin]]. This causes thinning and the wall balloons allowing gross enlargement to occur, as is common in the abdominal region of the aorta.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
==Histology==
The accumulation (swelling) is always in the '''tunica intima''', between the [[endothelium]] lining and the smooth muscle [[tunica media|middle layer]] of the artery wall. While the early stages, based on gross appearance, have traditionally been termed [[fatty streaks]] by pathologists, they are not composed of [[fat cells]] but of accumulations of [[white blood cells]], especially [[macrophages]], that have taken up oxidized [[low-density lipoprotein]] (LDL).
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
After they accumulate large amounts of cytoplasmic membranes (with associated high cholesterol content) they are called [[foam cell]]s. When foam cells die, their contents are released, which attracts more macrophages and creates an extracellular lipid core near the centre to inner surface of each atherosclerotic plaque.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Conversely, the outer, older portions of the plaque become more calcified, less metabolically active and more physically stiff over time.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
[[Vein]]s do not develop atheromata, because they are not subjected to the same haemodynamic pressure that arteries are, unless surgically moved to function as an artery, as in [[Coronary artery bypass surgery|bypass]] surgery.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
==Diagnosis==
[[File:Blausen 0052 Artery NormalvPartially-BlockedVessel.png|thumb|Illustration comparing a normal blood vessel and partially blocked vessel due to atherosclerotic plaque. Notice the enlargement & absence of much luminal narrowing.]]
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Because artery walls enlarge at locations with atheroma, detecting atheroma before death and autopsy has long been problematic at best. Most methods have focused on the openings of arteries; while these methods are highly relevant, they totally miss the atheroma within the arterial lumen.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Historically, arterial wall fixation, staining and thin section has been the gold standard for detection and description of atheroma, after death and autopsy. With special stains and examination, micro calcifications can be detected, typically within smooth muscle cells of the arterial media near the fatty streaks within a year or two of fatty streaks forming.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Interventional and non-interventional methods to detect atherosclerosis, specifically '''[[vulnerable plaque]]''' (non-occlusive or soft plaque), are widely used in research and clinical practice today.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
[[Carotid]] [[Intima-media thickness]] Scan (CIMT can be measured by B-mode [[ultrasonography]]) measurement has been recommended by the [[American Heart Association]] as the most useful method to identify atherosclerosis and may now very well be the gold standard for detection.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
[[Intravascular ultrasound]] is the current most sensitive method detecting and measuring more advanced atheroma within living individuals, but has had limited applications due to cost and body invasiveness.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
[[CT scan]]s using state of the art higher resolution spiral, or the higher speed [[Electron beam tomography|EBT]], machines have been the most effective method for detecting calcification present in plaque. However, the atheroma have to be advanced enough to have relatively large areas of calcification within them to create large enough regions of ~130 [[Hounsfield scale|Hounsfield units]] which a CT scanner's software can recognize as distinct from the other surrounding tissues. Typically, such regions start occurring within the heart arteries about 2–3 decades after atheroma start developing. The presence of smaller, spotty plaques may actually be more dangerous for progressing to acute [[myocardial infarction]].
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Arterial ultrasound, especially of the [[carotid]] arteries, with measurement of the thickness of the artery wall, offers a way to partially track the disease progression. As of 2006, the thickness, commonly referred to as IMT for intimal-medial thickness, is not measured clinically though it has been used by some researchers since the mid-1990s to track changes in arterial walls. Traditionally, clinical carotid ultrasounds have only estimated the degree of blood lumen restriction, [[stenosis]], a result of very advanced disease. The [[National Institute of Health]] did a five-year $5 million study, headed by [[medical research]]er [[Kenneth Ouriel]], to study intravascular ultrasound techniques regarding atherosclerotic plaque. More progressive clinicians have begun using IMT measurement as a way to quantify and track disease progression or stability within individual patients.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
[[Angiography]], since the 1960s, has been the traditional way of evaluating for atheroma. However, angiography is only motion or still images of dye mixed with the blood within the arterial [[Lumen (anatomy)|lumen]] and never show atheroma; the wall of arteries, including atheroma within the arterial wall remain invisible. The limited exception to this rule is that with very advanced atheroma, with extensive calcification within the wall, a halo-like ring of radiodensity can be seen in most older humans, especially when arterial lumens are visualized end-on. On cine-floro, cardiologists and radiologists typically look for these calcification shadows to recognize arteries before they inject any [[contrast agent]] during angiograms.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
===Classification of lesions===
* Type I: Isolated macrophage foam cells
* Type II: Multiple foam cell layers
* Type III: Preatheroma, intermediate lesion
* Type IV: Atheroma
* Type V: Fibroatheroma
* Type VI: Fissured, ulcerated, hemorrhagic, thrombotic lesion
* Type VII: Calcific lesion
* Type VIII: Fibrotic lesion
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
==Treatment==
Many approaches have been promoted as methods to reduce or reverse atheroma progression:
* eating a diet of raw fruits, vegetables, nuts, beans, berries, and grains;
* consuming foods containing [[omega−3]] fatty acids such as fish, fish-derived supplements, as well as flax seed oil, borage oil, and other non-animal-based oils;
* abdominal fat reduction;
* aerobic exercise;
* inhibitors of [[cholesterol]] synthesis (known as [[statins]]);
* low normal [[blood glucose]] levels ([[glycated hemoglobin]], also called [[HbA1c]]);
* micronutrient (vitamins, [[potassium]], and [[magnesium]]) consumption;
* maintaining normal, or healthy, blood pressure levels;
* aspirin supplement
* mouse studies indicated that subcutaneous administration of [[cyclodextrin|oligosaccharide 2-hydroxypropyl-β-cyclodextrin]] (2HPβCD) can solubilize [[cholesterol]], removing it from plaques. However, later work concluded that "treatment with 2HPβCD is ineffective in inducing atherosclerosis regression".
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
==History of research==
In [[developed countries]], with improved [[public health]], infection control and increasing life spans, atheroma processes have become an increasingly important problem and burden for society.
Atheromata continue to be the primary underlying basis for [[disability]] and [[death]], despite a trend for gradual improvement since the early 1960s (adjusted for patient age). Thus, increasing efforts towards better understanding, treating and preventing the problem are continuing to evolve.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
According to United States data, 2004, for about 65% of men and 47% of women, the first [[symptom]] of cardiovascular disease is [[myocardial infarction]] (heart attack) or sudden death (death within one hour of symptom onset).
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
A significant proportion of artery flow-disrupting events occur at locations with less than 50% [[Lumen (anatomy)|lumenal]] narrowing. [[Cardiac stress test]]ing, traditionally the most commonly performed non-invasive testing method for blood flow limitations, generally only detects lumen narrowing greater than about 75%, although some physicians advocate [[nuclear stress test]]s that can sometimes detect as little as 50%.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
The sudden nature of the complications of pre-existing atheroma, [[vulnerable plaque]] (non-occlusive or soft plaque), have led, since the 1950s, to the development of intensive care units and complex medical and surgical interventions. [[Angiography]] and later [[cardiac stress testing]] was begun to either visualize or indirectly detect [[stenosis]]. Next came [[Coronary artery bypass surgery|bypass surgery]], to plumb transplanted [[vein]]s, sometimes [[arteries]], around the stenoses and more recently [[angioplasty]], now including [[stent]]s, most recently drug coated stents, to stretch the stenoses more open.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Yet despite these medical advances, with success in reducing the symptoms of [[Angina pectoris|angina]] and reduced [[blood flow]], atheroma rupture events remain the major problem and still sometimes result in sudden disability and death despite even the most rapid, massive and skilled medical and surgical intervention available anywhere today. According to some clinical trials, bypass surgery and angioplasty procedures have had at best a minimal effect, if any, on improving overall survival. Typically mortality of bypass operations is between 1 and 4%, of angioplasty between 1 and 1.5%.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Additionally, these vascular interventions are often done only after an individual is symptomatic, often already partially disabled, as a result of the disease. It is also clear that both angioplasty and bypass interventions do not prevent future [[myocardial infarction|heart attack]].
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
The older methods for understanding atheroma, dating to before World War II, relied on autopsy data. Autopsy data has long shown initiation of [[fatty streak]]s in later childhood with slow asymptomatic progression over decades.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
One way to see atheroma is the very invasive and costly [[IVUS]] ultrasound technology; it gives us the precise volume of the inside [[intima]] plus the central [[Tunica media|media]] layers of about {{convert|25|mm|0|abbr=on}} of artery length. Unfortunately, it gives no information about the structural strength of the artery. Angiography does not visualize atheroma; it only makes the blood flow within [[blood vessels]] visible. Alternative methods that are non or less physically invasive and less expensive per individual test have been used and are continuing to be developed, such as those using [[computed tomography]] (CT; led by the [[electron beam tomography]] form, given its greater speed) and [[magnetic resonance imaging]] (MRI). The most promising since the early 1990s has been EBT, detecting calcification within the atheroma before most individuals start having clinically recognized symptoms and debility. Statin therapy (to lower cholesterol) does not slow the speed of calcification as determined by CT scan. MRI coronary vessel wall imaging, although currently limited to research studies, has demonstrated the ability to detect vessel wall thickening in asymptomatic high risk individuals. As a non-invasive, ionising radiation free technique, MRI based techniques could have future uses in monitoring disease progression and regression. Most visualization techniques are used in research, they are not widely available to most patients, have significant technical limitations, have not been widely accepted and generally are not covered by medical insurance carriers.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
From human clinical trials, it has become increasingly evident that a more effective focus of treatment is slowing, stopping and even partially reversing the atheroma growth process. There are several prospective epidemiologic studies including the [[Atherosclerosis Risk in Communities|Atherosclerosis Risk in Communities (ARIC) Study]] and the Cardiovascular Health Study (CHS), which have supported a direct correlation of [[Carotid]] [[Intima-media thickness]] (CIMT) with myocardial infarction and stroke risk in patients without cardiovascular disease history. The ARIC Study was conducted in 15,792 individuals between 5 and 65 years of age in four different regions of the US between 1987 and 1989. The baseline CIMT was measured and measurements were repeated at 4- to 7-year intervals by carotid B mode ultrasonography in this study. An increase in CIMT was correlated with an increased risk for CAD. The CHS was initiated in 1988, and the relationship of CIMT with risk of myocardial infarction and stroke was investigated in 4,476 subjects 65 years of age and below. At the end of approximately six years of follow-up, CIMT measurements were correlated with cardiovascular events.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Paroi artérielle et Risque Cardiovasculaire in Asia Africa/Middle East and Latin America (PARC-AALA) is another important large-scale study, in which 79 centres from countries in Asia, Africa, the Middle East, and Latin America participated, and the distribution of CIMT according to different ethnic groups and its association with the Framingham cardiovascular score was investigated. Multi-linear regression analysis revealed that an increased Framingham cardiovascular score was associated with CIMT, and carotid plaque independent of geographic differences.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Cahn et al. prospectively followed-up 152 patients with coronary artery disease for 6–11 months by carotid artery ultrasonography and noted 22 vascular events (myocardial infarction, transient ischemic attack, stroke, and coronary angioplasty) within this time period. They concluded that carotid atherosclerosis measured by this non-interventional method has prognostic significance in coronary artery patients.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
In the [[Rotterdam Study]], Bots et al. followed 7,983 patients >55 years of age for a mean period of 4.6 years, and reported 194 incident myocardial infarctions within this period. CIMT was significantly higher in the myocardial infarction group compared to the other group. Demircan et al. found that the CIMT of patients with acute coronary syndrome were significantly increased compared to patients with stable angina pectoris.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
It has been reported in another study that a maximal CIMT value of 0.956&nbsp;mm had 85.7% sensitivity and 85.1% specificity to predict angiographic CAD. The study group consisted of patients admitted to the cardiology outpatient clinic with symptoms of stable angina pectoris. The study showed CIMT was higher in patients with significant CAD than in patients with non-critical coronary lesions. Regression analysis revealed that thickening of the mean intima-media complex more than 1.0 was predictive of significant CAD our patients. There was incremental significant increase in CIMT with the number coronary vessel involved. In accordance with the literature, it was found that CIMT was significantly higher in the presence of CAD. Furthermore, CIMT was increased as the number of involved vessels increased and the highest CIMT values were noted in patients with left main coronary involvement. However, human clinical trials have been slow to provide clinical & medical evidence, partly because the asymptomatic nature of atheromata make them especially difficult to study. Promising results are found using carotid intima-media thickness scanning (CIMT can be measured by B-mode ultrasonography), B-vitamins that reduce a protein corrosive, [[homocysteine]] and that reduce neck [[carotid]] artery plaque volume and thickness, and stroke, even in late-stage disease.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
Additionally, understanding what drives atheroma development is complex with multiple factors involved, only some of which, such as [[lipoprotein]]s, more importantly lipoprotein subclass analysis, [[blood sugar]] levels and [[hypertension]] are best known and researched. More recently, some of the complex [[immune system]] patterns that promote, or inhibit, the inherent [[inflammation|inflammatory]] macrophage triggering processes involved in atheroma progression are slowly being better elucidated in animal models of atherosclerosis.
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
==See also==
{{col div|colwidth=40em}}
* [[Angiogram]]
* [[ApoA-1 Milano]]
* [[Atherosclerosis]]
* [[Atherothrombosis]]
* [[Coronary circulation]]
* [[Coronary catheterization]]
* [[Electron beam tomography|EBT]]
* [[Hemorheologic-Hemodynamic Theory of Atherosclerosis]]
* [[Lipoprotein]]
* [[LDL]], [[High density lipoprotein|HDL]], [[Intermediate density lipoprotein|IDL]] and [[VLDL]]
{{colend}}
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
==Further reading==
* {{cite journal |last1=Ornish |first1=D. |last2=Brown |first2=S.E. |last3=Billings |first3=J.H. |last4=Scherwitz |first4=L.W. |last5=Armstrong |first5=W.T. |last6=Ports |first6=T.A. |last7=McLanahan |first7=S.M. |last8=Kirkeeide |first8=R.L. |last9=Gould |first9=K.L. |last10=Brand |first10=R.J. |title=Can lifestyle changes reverse coronary heart disease? |journal=The Lancet |date=July 1990 |volume=336 |issue=8708 |pages=129–133 |doi=10.1016/0140-6736(90)91656-u |pmid=1973470 |s2cid=4513736 }}
* {{cite journal |last1=Gould |first1=K. Lance |last2=Ornish |first2=D |last3=Scherwitz |first3=L |last4=Brown |first4=S |last5=Edens |first5=RP |last6=Hess |first6=MJ |last7=Mullani |first7=N |last8=Bolomey |first8=L |last9=Dobbs |first9=F |last10=Armstrong |first10=WT |title=Changes in Myocardial Perfusion Abnormalities by Positron Emission Tomography After Long-term, Intense Risk Factor Modification |journal=JAMA |date=20 September 1995 |volume=274 |issue=11 |pages=894–901 |doi=10.1001/jama.1995.03530110056036 |pmid=7674504 }}
* {{cite journal |last1=Ornish |first1=Dean |last2=Scherwitz |first2=LW |last3=Billings |first3=JH |last4=Brown |first4=SE |last5=Gould |first5=KL |last6=Merritt |first6=TA |last7=Sparler |first7=S |last8=Armstrong |first8=WT |last9=Ports |first9=TA |last10=Kirkeeide |first10=RL |last11=Hogeboom |first11=C |last12=Brand |first12=RJ |title=Intensive Lifestyle Changes for Reversal of Coronary Heart Disease |journal=JAMA |date=16 December 1998 |volume=280 |issue=23 |pages=2001–7 |doi=10.1001/jama.280.23.2001 |pmid=9863851 |s2cid=21508600 }}
* {{cite journal |last1=Ornish |first1=Dean |title=Avoiding revascularization with lifestyle changes: the multicenter lifestyle demonstration project |journal=The American Journal of Cardiology |date=November 1998 |volume=82 |issue=10 |pages=72–76 |doi=10.1016/s0002-9149(98)00744-9 |pmid=9860380 }}
* {{cite journal |last1=Dod |first1=Harvinder S. |last2=Bhardwaj |first2=Ravindra |last3=Sajja |first3=Venu |last4=Weidner |first4=Gerdi |last5=Hobbs |first5=Gerald R. |last6=Konat |first6=Gregory W. |last7=Manivannan |first7=Shanthi |last8=Gharib |first8=Wissam |last9=Warden |first9=Bradford E. |last10=Nanda |first10=Navin C. |last11=Beto |first11=Robert J. |last12=Ornish |first12=Dean |last13=Jain |first13=Abnash C. |title=Effect of Intensive Lifestyle Changes on Endothelial Function and on Inflammatory Markers of Atherosclerosis |journal=The American Journal of Cardiology |date=February 2010 |volume=105 |issue=3 |pages=362–367 |doi=10.1016/j.amjcard.2009.09.038 |pmid=20102949 }}
* {{cite journal |last1=Silberman |first1=Anna |last2=Banthia |first2=Rajni |last3=Estay |first3=Ivette S. |last4=Kemp |first4=Colleen |last5=Studley |first5=Joli |last6=Hareras |first6=Dennis |last7=Ornish |first7=Dean |title=The Effectiveness and Efficacy of an Intensive Cardiac Rehabilitation Program in 24 Sites |journal=American Journal of Health Promotion |date=March 2010 |volume=24 |issue=4 |pages=260–266 |doi=10.4278/ajhp.24.4.arb |pmid=20232608 |s2cid=25915559 }}
* {{cite journal |last1=Glagov |first1=Seymour |last2=Weisenberg |first2=Elliot |last3=Zarins |first3=Christopher K. |last4=Stankunavicius |first4=Regina |last5=Kolettis |first5=George J. |title=Compensatory Enlargement of Human Atherosclerotic Coronary Arteries |journal=New England Journal of Medicine |date=28 May 1987 |volume=316 |issue=22 |pages=1371–1375 |doi=10.1056/NEJM198705283162204 |pmid=3574413 }}
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
== External links ==
{{Medical resources
|  DiseasesDB      = 1039
|  ICD10           = {{ICD10|I|70|9|i|70}}
|  ICD9            = {{ICD9|440}}
|  ICDO            =
|  OMIM            =
|  MedlinePlus     =
|  eMedicineSubj   =
|  eMedicineTopic  =
}}
{{Vascular diseases}}
</div>

<div lang="en" dir="ltr" class="mw-content-ltr">
{{二次利用|date=3 November 2023}}
[[Category:Vascular diseases]]
[[Category:Diseases of arteries, arterioles and capillaries]]
</div>

Export translations

Navigation menu

Search